Appointment of diagnostics industry veteran Pam Lacock as vice president of sales and growing manufacturing capabilities reflect continued momentum as Alps Dx advances its connected approach to oral fluid testing
RICHMOND, Va., Sept. 16, 2026 /PRNewswire/ — Ahead of the SOFT–TIAFT 2026 Joint Meeting this month, Alps Dx today announced the expansion of its commercial leadership and operations, reflecting continued momentum as the company builds the people, infrastructure, and capabilities behind its connected approach to modernizing oral fluid testing workflows.
The company has appointed diagnostics industry veteran Pam Lacock as vice president of sales and opened a new headquarters and initial manufacturing facility in Richmond, Virginia. Together, these investments represent the next phase of growth for Alps Dx as it builds the scientific, operational, and commercial capabilities needed to advance connected technologies across the oral fluid testing continuum.
“Building Alps Dx has always been about more than developing individual products. We are building the team, infrastructure, and capabilities needed to address workflow challenges across the oral fluid testing continuum,” said Ali Safavi, president, CEO and co-founder of Alps Dx. “The addition of Pam to our leadership team, together with the expansion of our operations, gives us an even stronger foundation as we move from development toward broader commercialization.”
Lacock brings more than 26 years of diagnostics and healthcare sales and business development experience to Alps Dx, including extensive experience with laboratory customers, health systems, large physician groups, drug monitoring, substance use disorder testing and strategic accounts. Before joining Alps Dx, she spent more than three years as vice president of business development at CompuNet Clinical Laboratories, where she oversaw sales, marketing and business development and helped grow the organization’s outreach business by 40%. Prior to CompuNet, Lacock spent 14 years with Quest Diagnostics in roles spanning drug monitoring, health plans and strategic accounts. Earlier in her career, she held sales roles with Siemens Healthcare Diagnostics and Bayer HealthCare Diagnostics across laboratory automation, chemistry, immunoassay and hematology. She has also received multiple President’s Club and other sales performance awards throughout her career.
As vice president of sales, Lacock will lead commercial strategy and customer development as Alps Dx expands engagement with laboratories and other organizations across the oral fluid testing continuum.
The leadership appointment comes as Alps Dx expands its physical footprint and operational capabilities. The company’s new 2,030-square-foot headquarters at 1519 Summit Avenue in Richmond will serve as its operational headquarters and initial manufacturing hub, supporting product development, systems integration, workflow testing, assembly activities, and commercial growth.
The new facility is part of a broader strategy to build the infrastructure needed to support Alps Dx as its portfolio and commercial activities grow. The company is also evaluating opportunities to expand its research, development, and manufacturing capabilities as it advances additional technologies across the oral fluid testing continuum.
The expansion builds on a year of continued momentum for Alps Dx. Earlier this year, the company introduced Alps Dx® Atelier™ at SLAS 2026 in collaboration with Hamilton Company. Atelier was developed to help automate and standardize the preanalytical stage of oral fluid testing workflows.
Alps Dx is developing a broader portfolio of purpose-built instruments, consumables, workflow software, and applications designed to connect and modernize different stages of the oral fluid testing continuum. The company’s approach spans collection, preparation, automation, and workflow connectivity, with the goal of creating more accessible, connected, and scalable oral fluid workflows.
“For years, oral fluid testing has offered enormous potential, but many workflows have remained manual and difficult to scale efficiently,” said Les Edinboro, PhD, co-founder and chief scientific officer of Alps Dx. “As we grow, we are building the scientific and operational capabilities needed to continue developing technologies that improve workflow connectivity, operational continuity, and scalability across the oral fluid testing continuum.”
Members of the Alps Dx team will attend the SOFT–TIAFT 2026 Joint Meeting, September 19–24 at the Hilton Chicago, joining forensic toxicologists, laboratory leaders, researchers, and industry partners from around the world. The meeting brings together the Society of Forensic Toxicologists and The International Association of Forensic Toxicologists for a rare joint gathering of the domestic and international forensic toxicology communities.
About Alps Dx
Alps Dx develops automated and connected technologies that modernize oral fluid workflows across laboratories, workplaces, and emerging decentralized collection environments. The company’s portfolio includes purpose-built instruments, consumables, workflow software, and applications designed to improve operational continuity, scalability and workflow efficiency across the oral fluid testing continuum. Alps Dx is headquartered in Richmond, Virginia.
View original content to download multimedia:https://www.prnewswire.com/news-releases/alps-dx-accelerates-growth-ahead-of-softtiaft-2026-with-new-commercial-leadership-headquarters-and-expanded-operations-302880579.html
SOURCE Alps Dx
